Brought to you by 
J&J to buy remainder of Crucell for €2bn
02 Jun 2011
Executive Summary
To build up a vaccines franchise, Johnson & Johnson has agreed to pay $2.2bn (€2bn) in cash (or $32.29 per share, a 24% premium) for the 82.1% of Crucell NV (developing antibodies and vaccines for infectious diseases) that J&J does not already own.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J to buy remainder of Crucell for €2bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice